Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

Bagsværd, Denmark, 16 May 2025 – Novo Nordisk today announced changes to its executive leadership and Board of Directors. As per mutual agreement with the Novo Nordisk Board, Lars Fruergaard ...

Lars Fruergaard Jørgensen, CEO of Novo Nordisk, to step down as company seeks a turnaround. Company found success with Wegovy and Ozempic, but share price has fallen by half in past year.

Lars Fruergaard Jorgensen had led Denmark’s Novo since 2017. Ritzau Scanpix/AFP via Getty Images. He told Reuters that discussions to replace Jorgensen had taken place over the past few weeks.

June 6 (Reuters) - Novo Nordisk's (NOVOb.CO) popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases ...

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...

(Reuters) -Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema ...

Novo Nordisk (NVO) is in focus on Friday after its long-time chief executive Lars Fruergaard Jørgensen announced his resignation following a mutual agreement with the board. Fruergaard will ...

Lars Fruergaard Jorgensen’s departure comes a week after the company downgraded its sales and profits forecast and follows a more than 50% decline in the company’s shares since mid-2024.

It’s the end of an era at Novo as longtime CEO Lars Fruergaard Jørgensen—who shepherded the company through its GLP-1 growth boom—heads for the exit.